KEGG   DRUG: Crizanlizumab
Entry
D11480                      Drug                                   
Name
Crizanlizumab (USAN/INN);
Crizanlizumab-tmca;
Adakveo (TN)
Product
ADAKVEO (Novartis Pharmaceuticals Corporation)
Formula
C6458H9948N1712O2050S58
Exact mass
146139.0612
Mol weight
146230.0981
Sequence
(Heavy chain)
QVQLVQSGAE VKKPGASVKV SCKVSGYTFT SYDINWVRQA PGKGLEWMGW IYPGDGSIKY
NEKFKGRVTM TVDKSTDTAY MELSSLRSED TAVYYCARRG EYGNYEGAMD YWGQGTLVTV
SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
SSGLYSLSSV VTVTSSNFGT QTYTCNVDHK PSNTKVDKTV ERKCCVECPP CPAPPVAGPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVQFNWYV DGMEVHNAKT KPREEQFNST
FRVVSVLTVV HQDWLNGKEY KCAVSNKGLP APIEKTISKT KGQPREPQVY TLPPSREEMT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPMLD SDGSFFLYSK LTVDKSRWQQ
GNVFSCSVMH EALHNHYTQK SLSLSPGK
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCKASQSVD YDGHSYMNWY QQKPGKAPKL LIYAASNLES
GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQSDENPL TFGGGTKVEI KRTVAAPSVF
IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
(Disulfide bridge: H22-H96, H136-L218, H149-H205, H224-H'224, H225-H'225, H228-H'228, H231-H'231, H262-H322, H368-H426, H'22-H'96, H'136-L'218, H'149-H'205, H'262-H'322, H'368-H'426, L23-L92, L138-L198, L'23-L'92, L'138-L'198)
  Type
Peptide
Remark
ATC code: B06AX01
Product: D11480<US>
Efficacy
Anti-anemic, Anti-P-selectin antibody
  Disease
Sickle cell disease [DS:H00229]
  Type
Monoclonal antibody
Comment
Treatment of sickle-cell disease
Target
SELP (CD62P) [HSA:6403] [KO:K06496]
  Pathway
hsa04514  Cell adhesion molecules
hsa04613  Neutrophil extracellular trap formation
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 B BLOOD AND BLOOD FORMING ORGANS
  B06 OTHER HEMATOLOGICAL AGENTS
   B06A OTHER HEMATOLOGICAL AGENTS
    B06AX Other hematological agents
     B06AX01 Crizanlizumab
      D11480  Crizanlizumab (USAN/INN) <US>
USP drug classification [BR:br08302]
 Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
  Crizanlizumab
   D11480  Crizanlizumab (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Cell adhesion molecules: other families
   Selectins
    SELP (CD62P)
     D11480  Crizanlizumab (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11480
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11480
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11480
Other DBs
CAS: 1690318-25-2
PubChem: 384585456
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system